Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 10, 2019 07:23 ET | Source: Aptinyx Inc.

Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain

NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with...
May 14, 2019 06:27 ET | Source: Aptinyx Inc.

Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update

Four Phase 2 studies expected to be ongoing by year end; multiple data read-outs anticipated in 2019 and 2020 Management to host conference call today at 8:00 a.m. ET EVANSTON, Ill., May 14, 2019 ...
May 07, 2019 07:23 ET | Source: Aptinyx Inc.

Aptinyx Appoints Henry Gosebruch to Its Board of Directors

EVANSTON, Ill., May 07, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
May 06, 2019 07:27 ET | Source: Aptinyx Inc.

Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019

EVANSTON, Ill., May 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
April 30, 2019 07:27 ET | Source: Aptinyx Inc.

Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers

Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure consistent with exposure observed at...
April 18, 2019 07:27 ET | Source: Aptinyx Inc.

Robust Analgesic Activity of Aptinyx’s NYX-2925 in Advanced DPN Patients Revealed Through Further Analysis of Data from Phase 2 Study

Mechanism of NYX-2925 is highly relevant in advanced DPN patients with longer duration of chronic pain Results support and inform future Phase 2 study, initiation expected in 2019 ...
April 04, 2019 08:00 ET | Source: Aptinyx Inc.

Aptinyx to Present at 18th Annual Needham Healthcare Conference

EVANSTON, Ill., April 04, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
April 03, 2019 07:27 ET | Source: Aptinyx Inc.

Data in Parkinson’s Disease Model in Non-human Primates Demonstrate Reversal of Cognitive Deficits with Novel NMDA Receptor Modulator, NYX-458

EVANSTON, Ill., April 03, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
March 28, 2019 07:07 ET | Source: Aptinyx Inc.

Aptinyx to Present Detailed Results from Phase 2 Painful DPN Study of NYX-2925 at American Pain Society Scientific Meeting

EVANSTON, Ill., March 28, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
March 22, 2019 07:27 ET | Source: Aptinyx Inc.

Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases

EVANSTON, Ill., March 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right